Curi Bio closes $10M oversubscribed Series A led by Dynamk Capital with new investors UTC Investment and DS Asset Management
Curi Bio closed a $10M oversubscribed Series A second closing to scale its human stem cell–based Curi Engine and Mantarray platforms, aiming to accelerate development of 3D engineered muscle tissue models for drug discovery.
More: GeekWire, MobiHealthNews
-
GeekWire / Charlotte Schubert: Curi Bio raises $10M to advance iPSC-based 3D tissue drug-discovery platforms including Mantarray
- MobiHealthNews / Laura Lovett: Curi Bio raises $10M Series A to advance Mantarry stem cell drug-discovery platform